Glenmark Pharmaceuticals on Saturday announced the launch of the first antiviral drug Favipiravir, under the brand name FabiFlu for the treatment of Covid-19 patients who are in initial and moderate stages.
The 200mg tablet is priced at Rs 103 and a pack of 34 costs Rs 3500/-.
FabiFlu stands to be the first oral favipiravir approved by all medical authorities in India.
It should be used on the prescription of the medical practitioner but cannot be sold across the counter as per the initial reports.
The recommended dosage being 9 tablets of 200 mg each on day one, followed by 4 tablets every day upto 14th day, as per the drug company.
But the manufacturing speed is a bit slow as it can supply only 82,500 patients in the first month. Glenmark is an Indian company based in Maharashtra. This proves to be the pathbreaking victory of India.
It has also licensed the marketing to Delhi-Brinton Pharma, Bengaluru Strides Pharma, Mumbai-Lasa Supergenerics and Hyderabad-Optimus Pharma.
